The Technical Analyst
Biovie Inc [BIVI]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Biovie Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-2.99% $0.490
America/New_York / 25 apr 2024 @ 09:35
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 26.93 mill |
| EPS: | -1.170 |
| P/E: | -0.420 |
| Earnings Date: | Apr 25, 2024 |
| SharesOutstanding: | 54.92 mill |
| Avg Daily Volume: | 2.62 mill |
| RATING 2024-04-24 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.420 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.07x |
| Company: PE -0.420 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.155 (-68.35%) $-0.335 |
| Date: 2024-04-25 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.404 - 0.606 ( +/- 19.98%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-04 | Do Cuong V | Buy | 10 000 | Common stock |
| 2024-03-04 | Do Cuong V | Buy | 5 000 | Warrants (right to buy) |
| 2023-12-11 | Kim Joanne Wendy | Buy | 5 000 | Common Stock |
| 2023-11-09 | Lang James Paul | Buy | 93 500 | Stock Option (right to buy) |
| 2023-11-09 | Gorlin Steve | Buy | 46 358 | Common Stock |
| INSIDER POWER |
|---|
| 91.63 |
| Last 94 transactions |
| Buy: 39 235 676 | Sell: 4 917 434 |
Forecast:
11:14 - $0.505
Live Trading Signals (every 1 min)
Forecast
1: 09:44 - $0.503
Forecast 2: 10:34 - $0.506
Forecast 3: 11:14 - $0.505
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.490 (-2.99% ) |
| Volume | 0.336 mill |
| Avg. Vol. | 2.62 mill |
| % of Avg. Vol | 12.82 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BIVI
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
BIVI
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.
Latest Press Releases
2024-04-25 08:00:00 - Press Release
Biovie Presents Data Showing Potential For Bezisterim (ne3107) To Reduce Inflammation And Restore Homeostasis In A Manner Correlated With Alzheimer's Disease And Biomarker Endpoints
Carson city, nev., april 25, 2024 (globe newswire) -- biovie inc. (nasdaq: bivi), (“biovie” or the “company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including neurological and neuro-degenerative disorders and liver disease, today announced that an oral presentation and poster revealing additional data on how bezisterim potentially restores homeostasis was presented at the 12th annual alzheimer's & parkinson's drug development summit held in boston, massachusetts april 23-25.
2024-04-18 08:00:00 - Press Release
Biovie To Present Data Showing How Ne3107 Potentially Restores Homeostasis Via Specific Genes Associated With Dementia, Metabolism, And Inflammation
Additionally, the company announced approval of the non-proprietary name “bezisterim” for ne3107 additionally, the company announced approval of the non-proprietary name “bezisterim” for ne3107
2024-04-12 09:00:00 - Press Release
Genetic Technologies And Biovie Interviews To Air On The Redchip Small Stocks, Big Money(tm) Show On Bloomberg Tv
Orlando, fl / accesswire / april 12, 2024 / redchip companies will air interviews with genetic technologies limited (nasdaq:gene) and biovie, inc. (nasdaq:bivi) on the redchip small stocks, big money™ show, a sponsored program on bloomberg tv, this saturday, april 13, at 7 p.m. eastern time (et).
2024-03-26 10:30:00 - Press Release
Lawsuit Notice: Investors Who Lost Money With Biovie Inc. (nasdaq: Bivi) Shares Should Contact The Shareholders Foundation
San diego , march 26, 2024 /prnewswire/ -- the shareholders foundation, inc. announced that a lawsuit is pending for certain investors in biovie inc. (nasdaq: bivi) shares. investors, who purchased shares of biovie inc. (nasdaq: bivi) prior to august 2021 and continue to hold any of those shares, have also certain options and should contact the shareholders foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
2024-03-19 16:30:00 - Press Release
Levi & Korsinsky Reminds Biovie Investors Of The Pending Class Action Lawsuit With A Lead Plaintiff Deadline Of March 19, 2024 – Bivi
New york, ny / accesswire / march 19, 2024 / if you suffered a loss on your biovie inc. (nasdaq:bivi) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biovie-lawsuit-submission-form?prid=71801&wire=1 or contact joseph e. levi, esq.
Latest News
2024-04-25 09:26:58 - Proactive Investors
BioVie presents new data showing lead drug asset may promote healthier aging
BioVie Inc (NASDAQ:BIVI) announced that it has presented data showing its lead drug asset NE3107 may restore homeostasis via specific genes associated with dementia, metabolism and inflammation at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit held in Boston from April 23 to 25. Additionally, the company said that bezisterim has been approved as the generic name for NE3107 by the United States Adopted Names Council and World Health Organization International Nonproprietary Names expert committee.
2024-03-12 10:55:22 - Zacks Investment Research
Bears are Losing Control Over BioVie Inc. (BIVI), Here's Why It's a 'Buy' Now
BioVie Inc. (BIVI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
2024-03-11 08:56:54 - Proactive Investors
BioVie to kick off Phase 2b trial for lead asset in Parkinson's disease in late-summer
BioVie Inc (NASDAQ:BIVI) told investors it has secured sufficient funds through a recently completed financing to progress its near-term clinical priority, developing its lead asset NE3107 for Parkinson's disease. It increased its cash balance by approximately $18.8 million after closing an equity financing round last week for gross proceeds of $21 million.
2024-03-01 10:57:13 - InvestorPlace
Why Is BioVie (BIVI) Stock Up 100% Today?
BioVie (NASDAQ: BIVI ) stock is rocketing higher on Friday announed positive data from two clinical trials of NE3107. NE3107 is BioVie's inhibitor of inflammatory activation of ERK and NFkB.
2024-03-01 09:49:57 - Proactive Investors
BioVie shares surge on lead asset NE3107's potential to improve Parkinson's Disease symptoms
BioVie Inc (NASDAQ:BIVI) shares surged 130% in early trade on Friday after the company revealed that its lead asset NE3107 has demonstrated the potential to improve motor and non-motor symptoms in patients with Parkinson's disease in a mid-stage clinical trial. The company said data from its Phase 2a trial showed Parkinson's Disease patients treated with NE3107 experienced significant improvements in non-motor symptoms and motor control, while patients in the placebo arm worsened.
2023-12-11 11:18:45 - Zacks Investment Research
BioVie Inc. (BIVI) Loses -46.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for BioVie Inc. (BIVI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
2023-11-30 12:01:28 - Zacks Investment Research
BioVie (BIVI) Falls 61% Despite Upbeat Alzheimer's Study Data
BioVie (BIVI) stock plunges 61% in spite of positive phase III Alzheimer's Disease study results due to significant study conduct violations and protocol deviations reported by the company.
2023-11-29 11:38:46 - InvestorPlace
Why Is BioVie (BIVI) Stock Down 63% Today?
BioVie (NASDAQ: BIVI ) stock is falling on Wednesday after the company released data from a Phase 3 clinical trial of its Alzheimer's Disease treatment candidate NE3107. Unfortunately for investors in BIVI stock, that study failed to meet its primary endpoint of statistical significance.
2023-11-29 08:48:05 - Proactive Investors
BioVie reports efficacy data from NE3107 Phase 3 trial for Alzheimer's Disease
BioVie Inc (NASDAQ:BIVI), the clinical-stage company specializing in drug therapies for neurological disorders, revealed new results from the Phase 3 trial of NE3107 in patients with mild to moderate Alzheimer's Disease (AD). The trial, initiated during the COVID-19 pandemic, enrolled 439 patients across 39 sites.
2023-11-22 20:12:00 - Seeking Alpha
BioVie: Cautiously Optimistic Ahead Of Phase 3 Alzheimer's Data Unblinding
Blinded Phase 3 data of NE3107 in Alzheimer's appear to indicate robust cognitive and biomarker efficacy. Market is significantly undervaluing the probability of a successful data unblinding expected shortly after Thanksgiving. Potential to be the first neurodegenerative biotech to show significant improvement in cognition Alzheimer's disease with suspected disease modification.